<DOC>
	<DOCNO>NCT02414685</DOCNO>
	<brief_summary>TIP 1st line treatment GCTs patient unfavorable decline serum tumor marker 1 cycle BEP regimen.TIP administer patient progression , unacceptable toxicity , complete response inability subject comply study requirement .</brief_summary>
	<brief_title>First Line TIP Poor Prognosis TGCTs .</brief_title>
	<detailed_description>Cycle 1 : BEP regimen Serum tumor marker day 18-21 : â€¢Patients unfavorable pattern tumor marker decrease 1 cycle BEP receive 4 cycle TIP . TIP regimen : - Taxol 250 mg/ m2 iv day 1 - Ifosfamid 1,2 g/ m2/ day iv x 5 day - Cisplatin 20 mg/ m2/ day iv x 5 day One cycle therapy consist 22 day . Estimated duration treatment : Until progression , unacceptable toxicity , complete response inability subject comply study requirement .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Patients older 16 year . Evidence NSGCT base histologic examination base clinical evidence high serum HCG AFP level ( case clinical emergency , therapy start pathologic sample obtain tumor marker elevate ) Testicular , retroperitoneal , mediastinal primary site . Evidence disseminate disease ( clinical stage II III ) . Disease classify poor prognosis accord IGCCCG criterion : Primary mediastinal NSGCT Nonpulmonary visceral metastasis HCG &gt; 50,000 UI/l , AFP &gt; 10,000 ng/ml , LDH &gt; 10 time upper normal value . No prior chemotherapy . No previous carcinoma , except basalcell carcinoma skin . Adequate renal function : measure calculated creatinine clearance &gt; 60 ml/min . Absolute granulocyte count &gt; = 1,500/mm3 , platelet &gt; = 100,000 mm3 , bilirubine &lt; = 1.5 fold upper normal value . Unfavorable tumor marker decline 1.cycle BEP Signed informed consent . Patients infected Human Immunodeficiency Virus ( HIV ) . Patients fit inclusion criterion .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>poor-prognosis germ cell cancer , paclitaxel , ifosfamid cisplatin regimen , tumor marker decline</keyword>
</DOC>